584 related articles for article (PubMed ID: 7473177)
1. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril.
Edling O; Bao G; Feelisch M; Unger T; Gohlke P
J Pharmacol Exp Ther; 1995 Nov; 275(2):854-63. PubMed ID: 7473177
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride.
Friehe H; Ney P
Arzneimittelforschung; 1997 Feb; 47(2):132-44. PubMed ID: 9079232
[TBL] [Abstract][Full Text] [Related]
3. Compared properties of trandolapril, enalapril, and their diacid metabolites.
Chevillard C; Jouquey S; Bree F; Mathieu MN; Stepniewski JP; Tillement JP; Hamon G; Corvol P
J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S11-5. PubMed ID: 7527095
[TBL] [Abstract][Full Text] [Related]
4. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?
van den Meiracker AH; Man in 't Veld AJ; Admiraal PJ; Ritsema van Eck HJ; Boomsma F; Derkx FH; Schalekamp MA
J Hypertens; 1992 Aug; 10(8):803-12. PubMed ID: 1325513
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
Wada T; Inada Y; Ojima M; Sanada T; Shibouta Y; Nishikawa K
Hypertens Res; 1996 Jun; 19(2):75-81. PubMed ID: 10968199
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
Aono J; Koga T; Yamazaki T; Shiraki Y; Sakai K
Arch Int Pharmacodyn Ther; 1988; 292():203-22. PubMed ID: 3293542
[TBL] [Abstract][Full Text] [Related]
7. [Renal tissue angiotensins during converting enzyme inhibition of angiotensin I in spontaneously hypertensive rat].
Ingert C; Grima M; Michel B; Barthelmebs M; Imbs JL
Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1135-41. PubMed ID: 9404423
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibition augments the expression of rat elastase-2, an angiotensin II-forming enzyme.
Becari C; Teixeira FR; Oliveira EB; Salgado MC
Am J Physiol Heart Circ Physiol; 2011 Aug; 301(2):H565-70. PubMed ID: 21602471
[TBL] [Abstract][Full Text] [Related]
9. Novel antihypertensive hexa- and heptapeptides with ACE-inhibiting properties: from the in vitro ACE assay to the spontaneously hypertensive rat.
Ruiz-Giménez P; Marcos JF; Torregrosa G; Lahoz A; Fernández-Musoles R; Valles S; Alborch E; Manzanares P; Salom JB
Peptides; 2011 Jul; 32(7):1431-8. PubMed ID: 21605609
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive effects of CI-907 (indolapril): a novel nonsulfhydryl angiotensin converting enzyme inhibitor.
Ryan MJ; Boucher DM; Cohen DM; Essenburg AD; Major TC; Mertz TE; Olszewski BJ; Randolph AE; Singer RM; Kaplan HR
J Pharmacol Exp Ther; 1984 Feb; 228(2):312-8. PubMed ID: 6319675
[TBL] [Abstract][Full Text] [Related]
11. CI-906 and CI-907: new orally active nonsulfhydryl angiotensin-converting enzyme inhibitors.
Kaplan HR; Cohen DM; Essenburg AD; Major TC; Mertz TE; Ryan MJ
Fed Proc; 1984 Apr; 43(5):1326-9. PubMed ID: 6323223
[TBL] [Abstract][Full Text] [Related]
12. Effects of enalapril on the expression of cardiac angiotensin-converting enzyme and angiotensin-converting enzyme 2 in spontaneously hypertensive rats.
Yang Z; Yu X; Cheng L; Miao LY; Li HX; Han LH; Jiang WP
Arch Cardiovasc Dis; 2013 Apr; 106(4):196-201. PubMed ID: 23706365
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological properties of FPL 63547, a novel inhibitor of angiotensin-converting enzyme.
Carr RD; Higgs L; Killingback PG; Nicol AK; O'Connor SE; Robson A; Wells E; Simpson WT
Br J Pharmacol; 1990 May; 100(1):83-9. PubMed ID: 2164863
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the actions of the angiotensin-converting enzyme inhibitors enalapril and S-9490-3 in sodium-deplete and sodium-replete spontaneously hypertensive rats.
DiNicolantonio R; Doyle AE
J Cardiovasc Pharmacol; 1985; 7(5):937-42. PubMed ID: 2413304
[TBL] [Abstract][Full Text] [Related]
15. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
[TBL] [Abstract][Full Text] [Related]
16. Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition.
Cawello W; Boekens H; Waitzinger J; Miller U
Int J Clin Pharmacol Ther; 2002 Jan; 40(1):9-17. PubMed ID: 11837383
[TBL] [Abstract][Full Text] [Related]
17. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats.
Ravati A; Junker V; Kouklei M; Ahlemeyer B; Culmsee C; Krieglstein J
Eur J Pharmacol; 1999 May; 373(1):21-33. PubMed ID: 10408248
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological properties of the converting enzyme inhibitor, enalapril maleate (MK-421).
Sweet CS
Fed Proc; 1983 Feb; 42(2):167-70. PubMed ID: 6295819
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme inhibition with quinapril (CI-906) and captopril in spontaneously hypertensive rats with suppressed renin-angiotensin system.
Säynävälammi P; Pörsti I
Methods Find Exp Clin Pharmacol; 1987 Jun; 9(6):325-31. PubMed ID: 3309510
[TBL] [Abstract][Full Text] [Related]
20. Prolonged inhibition of local angiotensin-converting enzyme after single or repeated treatment with quinapril in spontaneously hypertensive rats.
Nakajima T; Yamada T; Setoguchi M
J Cardiovasc Pharmacol; 1992 Jan; 19(1):102-7. PubMed ID: 1375675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
